33871816|t|Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
33871816|a|Entrectinib (Rozlytrek ) is an orally active, CNS-penetrant, small-molecule, selective inhibitor of the tropomyosin receptor tyrosine kinases TRKA/B/C [encoded by the neurotrophic tyrosine receptor kinase (NTRK) genes NTRK1/2/3, respectively], the proto-oncogene tyrosine-protein kinase ROS1 (ROS1) and the anaplastic lymphoma kinase gene (ALK). It is approved for the treatment of adults and paediatric patients aged >= 12 years with NTRK fusion-positive (NTRK+) solid tumours and adults with ROS1 fusion-positive (ROS1+) non-small-cell lung cancer (NSCLC). In trials in adults, entrectinib induced clinically meaningful and durable systemic responses in tyrosine kinase inhibitor (TKI)-naive patients with locally-advanced or metastatic NTRK+ solid tumours or ROS1+ NSCLC, irrespective of the presence or absence of CNS metastases at baseline. Moreover, entrectinib demonstrated substantial intracranial efficacy in patients with baseline CNS metastases. Entrectinb efficacy in paediatric patients was established on the basis of extrapolation of clinical trial data from adults with NTRK+ solid tumours and children and adolescents aged < 21 years with recurrent or refractory NTRK+ CNS/solid tumours. Entrectinib was generally well tolerated, with a manageable safety profile. Thus, entrectinib expands the range of treatment options for advanced NTRK+ solid tumours and ROS1+ NSCLC, and may be of particular value in patients with existing CNS metastases and those who are at risk of developing CNS metastases.
33871816	0	11	Entrectinib	Chemical	MESH:C000607349
33871816	31	44	Solid Tumours	Disease	MESH:D009369
33871816	49	53	ROS1	Gene	6098
33871816	55	60	NSCLC	Disease	MESH:D002289
33871816	62	73	Entrectinib	Chemical	MESH:C000607349
33871816	75	84	Rozlytrek	Chemical	MESH:C000607349
33871816	280	289	NTRK1/2/3	Gene	4914;4915;4916
33871816	349	353	ROS1	Gene	6098
33871816	355	359	ROS1	Gene	6098
33871816	466	474	patients	Species	9606
33871816	526	539	solid tumours	Disease	MESH:D009369
33871816	556	560	ROS1	Gene	6098
33871816	578	582	ROS1	Gene	6098
33871816	585	611	non-small-cell lung cancer	Disease	MESH:D002289
33871816	613	618	NSCLC	Disease	MESH:D002289
33871816	642	653	entrectinib	Chemical	MESH:C000607349
33871816	756	764	patients	Species	9606
33871816	807	820	solid tumours	Disease	MESH:D009369
33871816	824	828	ROS1	Gene	6098
33871816	830	835	NSCLC	Disease	MESH:D002289
33871816	884	894	metastases	Disease	MESH:D009362
33871816	918	929	entrectinib	Chemical	MESH:C000607349
33871816	980	988	patients	Species	9606
33871816	1007	1017	metastases	Disease	MESH:D009362
33871816	1019	1029	Entrectinb	Chemical	-
33871816	1053	1061	patients	Species	9606
33871816	1154	1167	solid tumours	Disease	MESH:D009369
33871816	1248	1265	CNS/solid tumours	Disease	MESH:D016543
33871816	1267	1278	Entrectinib	Chemical	MESH:C000607349
33871816	1349	1360	entrectinib	Chemical	MESH:C000607349
33871816	1419	1432	solid tumours	Disease	MESH:D009369
33871816	1437	1441	ROS1	Gene	6098
33871816	1443	1448	NSCLC	Disease	MESH:D002289
33871816	1484	1492	patients	Species	9606
33871816	1511	1521	metastases	Disease	MESH:D009362
33871816	1566	1576	metastases	Disease	MESH:D009362
33871816	Association	MESH:D002289	6098
33871816	Negative_Correlation	MESH:C000607349	MESH:D009369
33871816	Negative_Correlation	MESH:C000607349	MESH:D009362
33871816	Negative_Correlation	MESH:C000607349	6098
33871816	Negative_Correlation	MESH:C000607349	MESH:D002289

